Stockscreener 앱 받기
17.98
1.64%
-0.30
시간 외 거래:
17.90
-0.08
-0.44%
전일 마감가:
$18.28
열려 있는:
$18.27
하루 거래량:
469.66K
Relative Volume:
0.06
시가총액:
$991.95M
수익:
$29.71M
순이익/손실:
$-69.15M
주가수익비율:
-18.54
EPS:
-0.97
순현금흐름:
$-52.28M
1주 성능:
-1.69%
1개월 성능:
-2.34%
6개월 성능:
+48,233%
1년 성능:
+48,233%
1일 변동 폭
$17.90
$19.20
1주일 범위
$17.90
$20.69
52주 변동 폭
$16.80
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Compare AKTS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
17.98 | 1.01B | 29.71M | -69.15M | -52.28M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | H.C. Wainwright | Buy |
| 2026-02-03 | 개시 | BofA Securities | Buy |
| 2026-02-03 | 개시 | JP Morgan | Overweight |
| 2026-02-03 | 개시 | Leerink Partners | Outperform |
| 2026-02-03 | 개시 | TD Cowen | Buy |
| 2024-01-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | 개시 | B. Riley Securities | Buy |
| 2021-02-02 | 재확인 | Craig Hallum | Buy |
| 2021-01-15 | 재확인 | Craig Hallum | Buy |
| 2019-09-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | 개시 | Craig Hallum | Buy |
| 2018-11-30 | 개시 | Lake Street | Buy |
| 2018-06-22 | 개시 | Loop Capital | Buy |
| 2018-02-09 | 개시 | Drexel Hamilton | Buy |
모두보기
Aktis Oncology Inc 주식(AKTS)의 최신 뉴스
Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Little-known Cambridge firm plans public debut to fund pancreatic cancer trial - The Business Journals
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
This Aktis Oncology analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
AKTS: Innovative radiopharmaceutical platform advances with strong pipeline, partnerships, and cash runway - TradingView
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aktis Oncology Fast Track Win Highlights AKY-1189 Potential And Key Risks - Sahm
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Momentum And Ongoing Losses - Sahm
Aktis Oncology, Inc. (AKTS) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks
AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView
AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView
BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKTS Technical Analysis & Stock Price Forecast - Intellectia AI
IPO Tracker 2026: Generate Clocks Largest IPO Since 2024 With $400M Raise - BioSpace
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks
Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget
Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com
Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com
Flagship-Backed Generate Biomedicines Seeks $425 Million in IPO - Bloomberg.com
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO - Reuters
Ken Herrmann Net Worth (2026) - GuruFocus
US Index IPO ForecastMar26: 8 Additions Including Medline & BETA Technologies - Smartkarma
Huge insider buying now at this insurance giant and 2 biotechs - MSN
2026 kicks off with $10.8B January financing haul - BioWorld MedTech
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTVB
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics raises $381M in IPO - Axios
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com
Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential - TipRanks
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - Reuters
Eikon ?Therapeutics targets $908 million valuation in US IPO - marketscreener.com
Eikon sets $274M goal for upcoming stock market debut - Fierce Biotech
Carvina Capital: Strong Demand Lifts Aktis IPO - Barchart.com
Aktis Oncology prices IPO at $18 per share - MSN
Why Revolution Medicines Stock Surged by 11% Today - AOL.com
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - AOL.com
Investors Scoop Up Shares in Key Insurance and Biotech Companies - finance.coin-turk.com
‘No reasons to own’: Software stocks sink on fear of new AI tool - The Japan Times
Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying - Yahoo Finance
AKTS SEC FilingsAKTIS ONCOLOGY INC 10-K, 10-Q, 8-K Forms - Stock Titan
United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Nigeria
Aktis Oncology Inc (AKTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):